Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Rise In Computer-Related Injuries
While back pain, blurred vision and mouse-related injuries are now well-documented hazards of long-term computer use, the number of acute injuries connected to computers is rising rapidly. According to a study published in the July 2009 issue of the American Journal of Preventive Medicine, researchers from the Center for Injury Research and Policy and The Research Institute at Nationwide Children"s Hospital; and The Ohio State University College of Medicine, Columbus have found a more-than-sevenfold increase in computer-related injuries due to tripping over computer equipment, head injuries due to computer monitor falls and other physical incidents.

More Vigilant Monitoring For Seizures Among ICU Patients Encouraged
Two new studies published by neurologists at Columbia University Medical Center and NewYork-Presbyterian Hospital demonstrate a need for more vigilant monitoring for seizure activity among intensive care patients who may be experiencing subtle seizures that are typically unrecognized. These subtle seizures may be affecting patients" prognoses and causing long-term brain damage, death and severe disability.
News of the day
First Human Demonstration Of Significant, Persistent Antibody Response Using Electroporation-Delivered DNA Vaccine Published In Human Gene Therapy
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today new data representing what Inovio believes to be the first demonstration of a significantly increased and persistent level of antibody response generated by a DNA vaccine delivered using electroporation.
Oncology

DOR BioPharma Receives EMEA Agreement On The Design Of Its Confirmatory Phase 3 Clinical Trial Of OrBec(R) In GI GVHD

further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA"s requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR"s most recent reports on Forms 10-Q and 10-K. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a result of new information or future events. DOR BioPharma, Inc

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009